Ramsey, Bonnie W.

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 2,198

A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation

Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 2,195

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 1,622

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet

Cystic Fibrosis Research AdvancesPharmacogenetics and Drug Metabolism

Cited by 1,414

Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients

Smith, E. E., Buckley, D. G., Wu, Z., Saenphimmachak, C., Hoffman, L. R., D’Argenio, D. A., Miller, S. I., Ramsey, B. W., Speert, D. P., Moskowitz, S. M., et al. (2006) · Proceedings of the National Academy of Sciences

Cystic Fibrosis Research AdvancesBacterial biofilms and quorum sensing

Cited by 1,319

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Sass, L. A., Tullis, E., et al. (2018) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 726

Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis

Rowe, S. M., Heltshe, S. L., Gonska, T., Donaldson, S. H., Borowitz, D., Gelfond, D., Sagel, S. D., Khan, U., Mayer-Hamblett, N., Van Dalfsen, J. M., et al. (2014) · American Journal of Respiratory and Critical Care Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 492

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Davies, J. C., Moskowitz, S. M., Brown, C., Horsley, A., Mall, M. A., McKone, E. F., Plant, B. J., Prais, D., Ramsey, B. W., Taylor-Cousar, J. L., et al. (2018) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 331

Susceptibility Testing of Pseudomonas aeruginosa Isolates and Clinical Response to Parenteral Antibiotic Administration

Smith, A. L., Fiel, S. B., Mayer-Hamblett, N., Ramsey, B., & Burns, J. L. (2003) · Chest

Cystic Fibrosis Research AdvancesBacterial biofilms and quorum sensing

Cited by 307

Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations. eICE study results

Lechtzin, N., Mayer-Hamblett, N., West, N. E., Allgood, S., Wilhelm, E., Khan, U., Aitken, M. L., Ramsey, B. W., Boyle, M. P., Mogayzel, P. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine

Cystic Fibrosis Research AdvancesChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 127

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles

Taylor-Cousar, J. L., Mall, M. A., Ramsey, B. W., McKone, E. F., Tullis, E., Marigowda, G., McKee, C. M., Waltz, D., Moskowitz, S. M., Savage, J., et al. (2019) · ERJ Open Research

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 105

Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study

Daines, C. L., Tullis, E., Costa, S., Linnemann, R. W., Mall, M. A., McKone, E. F., Polineni, D., Quon, B. S., Ringshausen, F. C., Rowe, S. M., et al. (2023) · European Respiratory Journal

Cystic Fibrosis Research AdvancesPharmacogenetics and Drug Metabolism

Cited by 100